Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-Researchers and Healthcare Providers
-Research Grants Program
 NHF-Baxter Clinical Fellowship
-NHF/Novo Nordisk Career Development Award
 Judith Graham Pool Postdoctoral Research Fellowships
 Nursing Excellence Fellowship
 Social Work Excellence Fellowship
 Physical Therapy Excellence Fellowship
 Medical and Scientific Advisory Council
 Nursing Working Group
 Social Work Working Group
 Physical Therapy Working Group
 Comprehensive Medical Care - Hemophilia Treatment Centers
 Cell Based Coagulation Animation
 Rare Bleeding and Clotting Disorders Resource Room
 The Partners in Bleeding Disorders Education Program
 NHF/Novo Nordisk HANDI Library

 

 

 
Previous Career Development Program Recipient
 

2011 Recipient



Jordan A. Shavit, MD, PhD
University of Michigan,
Ann Arbor, MI

Dr. Shavit’s research project focuses on better understanding the genetic and molecular pathways that modify or regulate hemostasis through the use of a zebrafish model. Specifically, he will utilize zebrafish genetics to potentially identify the modifier genes that result in reduced or absent bleeding. This innovative proposal may lead to improved therapeutic approaches, especially with regard to screening or potentially tailoring treatments to specific patients. As the recipient of our 2011 NHF/Novo Nordisk Career Development Award, Dr. Shavit will receive support for up to three years.

Dr. Shavit received his undergraduate degree in cell and molecular biology from the University of Michigan and both his MD and PhD from Northwestern University. Prior to his appointment as an Assistant Professor of Pediatrics and Communicable Diseases at the University of Michigan in 2009, he spent four years as a postdoctoral research fellow at the University of Michigan under the mentorship of Dr. David Ginsburg. Dr. Shavit is also a former NHF-Baxter Clinical Fellow, having received the award in 2006-2008.

The funding for this award is made possible thanks to a generous grant from Novo Nordisk to NHF’s Research Catalyst Fund.

2009-2012 Recipient



Keri C. Smith, Ph.D.
University of Texas
Health Science Center at Houston

“Identification and Amelioration of T-cell Mediated Inflammatory Cytokines that Contribute to Anti-Factor VIII Inhibitor Formation in Hemophilia A.”

Dr. Smith’s research focuses on better understanding the development of factor VIII inhibitors. Specifically, she will focus on the effects of chemical signals, or cytokines, secreted by helper T cells on the development of inhibitor antibodies. She hypothesizes that certain cells, called Th17 cells, play an important role in the development of these antibodies by stimulating inflammation and driving the immune response toward inhibitor production. Dr. Smith received a BS from the University of Delaware before earning her Ph.D. from Montana State University. Prior to her appointment as an Assistant Professor at the University of Texas Medical School at Houston, she spent four years as a postdoctoral research fellow at the University of Michigan.

2008-2009 Recipient



Veronica H. Flood, MD

Medical College of Wisconsin

“Studies of VWF Function in VWF-Platelet and VWF-FVIII Interactions”

Dr. Flood earned her undergraduate degree from Harvard University in 1995 and her doctorate from Tufts University in 1999. She is board certified in pediatrics as well as pediatric hematology/oncology. She has been serving as an Assistant Professor at the Medical College of Wisconsin, where she has been performing research and seeing patients since 2006.

As part of her NHF Career Development Award, Dr. Flood will study the common variants and interactions of the von Willebrand factor molecule as a means to enhance overall understanding and eventually improve upon current methods of von Willebrand disease testing. Using mouse models, she will investigate diagnostic alternatives by examining the interaction between ristocetin and its ability to bind to von Willebrand factor. As Dr. Flood states in her summary, “Improved testing for VWD will prevent patients with normal VWF function from receiving unnecessary treatment, while allowing more accurate assessment of patients with true defects in VWD.”

 

CAREER DEVELOPMENT AWARDs

In Bleeding Disorders Research

 

2000 - 2009

2008 -present

 

 

 

 

 

 

2007-present

 

 

 

 

 

 

2007-present

 

 

 

 

 

 

 

2007-present

 

 

 

 

 

 

 

2006-2009

 

 

 

 

 

 

 

2005–2008

 

 

 

 

 

 

2005–2008

 

 

 

 

 

 

 

 

 

2004-2007

 

 

 

 

 

 

 2004-2007

 

 

 

 

 

 

2004-2007

 

 

 

 

 

 

 

2004-2007

 

 

 

 

 

 

2003-2006

 

 

 

 

 

 

 

2003-2006

 

 

 

 

 

 

 

 

2003-2006

 

 

 

 

 

 

Veronica Flood, MD

Medical College of Wisconsin

Milwaukee, WI

 

Project Title: Studies of VWF Function in VWF-Platelet and VWF-FVIII Interactions

 

 

Alisa Wolberg, Ph.D.

University of North Carolina at Chapel Hill

Chapel Hill, NC

 

Project Title: Recombinant Factor VIIa and RL Platelets as a Hemophilia Therapy

 

 

Qizhen Shi, MD, Ph.D.

Medical College of Wisconsin

Milwaukee, WI

 

Project Title: Immune Response in Platelet-Derived FVIII Gene Therapy of Murine Hemophilia A

 

 

Jay Lozier, MD, Ph.D.

US Food and Drug Administration

Rockville, MD

 

Project Title: Pharmacogenomics of Hemophilia Therapy: Genetics of Inhibitor Antibody Response

 

 

Yashuhiro Ikeda, Ph.D., DVM

Mayo Clinic

Rochester, MN

 

Project Title: Self-Regulating HIV Vectors for Hemophilia A Gene Therapy

 

 

Donald L. Yee, MD

Texas Children’s Cancer Center

Houston, Texas

 

Project Title: Platelets as Modifiers of Phenotype in Hemophilia A

 

 

Bradley E. Aouizerat, Ph.D.

University of California San Francisco

San Francisco, California

 

Project Title: A Disease-Specific DNA Chip for von Willebrand Disease

 

 

 

 

 

Kathleen Brummel-Ziedins, Ph.D.

University of Vermont

Burlington, Vermont

 

Project Title: Individualized Phenotypic Prophylaxis for Hemophilia

 

 

Suzie Hwang Pun, Ph.D.

University of Washington

Seattle, Washington

 

Project Title: Development of Nanoparticles for Non-viral Hemophilia Gene Therapy

 

 

Bin Zhang, Ph.D.

University of Michigan

Ann Arbor, Michigan

 

Project Title: Regulation of Factor V and VIII Secretion by an ER to Golgi Transport Receptor

 

 

Huang-Ge Zhang, DVM, MD, Ph.D.

University of Alabama at Birmingham

Birmingham, Alabama

 

Project Title: Depletion of Immune Response to AAV-F.IX

 

 

Lingfei Xu, MD

Washington University

St. Louis, Missouri

 

Project Title: Retroviral Vector-Mediated Neonatal Gene Therapy for Hemophilia A

 

 

Paul E. Monahan, MD

University of North Carolina

Chapel Hill, North Carolina

 

Project Title: Double-stranded Adeno-associated Virus (dsAAV) Vectors to Improve Efficacy and

                     to Evaluate Safety of Factor IX Gene Therapy

 

 

Hiroyuki Nakai, MD, Ph.D.

Stanford University School of Medicine

Stanford, California

 

Project Title: Establishing the Factors Responsible for Hepatocyte Permissiveness to AAV Vectors

 

2002-2004

 

 

 

 

 

 

2002-2005

 

Yubin Kang, MD

University of Iowa College of Medicine

Iowa City, Iowa

 

Project Title: Non-primate Lentiviral Vector-Based Gene Therapy for Hemophilia A

 

 

Carol H. Miao, Ph.D.

University of Washington

Seattle, WA

 

Project Title: Nonviral Gene Delivery for Hemophilia

 

 

 

2002-2005

 

Frank Park, Ph.D.

Louisiana State University

New Orleans, LA

 

Project Title: Gene Transfer of Factor VIII to the Liver in Vivo

 

.

2001-2004

 

Hengjun Chao, MD

University of North Carolina

Chapel Hill, North Carolina

 

Project Title: Gene Therapy for Hemophilia B by Direct Intramuscular Injections of Recombinant

                     Adeno Associated Virus Serotype Vectors

 

2000-2003

 

Steven Wesley Pipe, MD

University of Michigan

Ann Arbor, Michigan

 

Project Title: Development and Characterization of Novel Genetically Engineered Factor VIII

                     Molecules with Increased Activity and Stability

 

2000-2003

 

Roland W. Herzog, Ph.D.

The Children’s Hospital of Philadelphia

Philadelphia, Pennsylvania

 

Project Title:  Immunology of Liver-Derived Expression of Factor IX from AAV Vectors

 

2000-2003

 

Tal Kafri, M.D., Ph.D.

University of North Carolina

Chapel Hill, North Carolina

 

Project Title: Correction of Hemophilia with Lentiviral Vectors